Accéder au contenu
Merck
  • The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.

The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.

Biochimica et biophysica acta (2000-01-15)
M Abramovitz, M Adam, Y Boie, M Carrière, D Denis, C Godbout, S Lamontagne, C Rochette, N Sawyer, N M Tremblay, M Belley, M Gallant, C Dufresne, Y Gareau, R Ruel, H Juteau, M Labelle, N Ouimet, K M Metters
RÉSUMÉ

Stable cell lines that individually express the eight known human prostanoid receptors (EP(1), EP(2), EP(3), EP(4), DP, FP, IP and TP) have been established using human embryonic kidney (HEK) 293(EBNA) cells. These recombinant cell lines have been employed in radioligand binding assays to determine the equilibrium inhibitor constants of known prostanoid receptor ligands at these eight receptors. This has allowed, for the first time, an assessment of the affinity and selectivity of several novel compounds at the individual human prostanoid receptors. This information should facilitate interpretation of pharmacological studies that employ these ligands as tools to study human tissues and cell lines and should, therefore, result in a greater understanding of prostanoid receptor biology.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
17-Phenyl-tri-norprostaglandin F-ethyl amide, ≥95%, solid